Methotrexate treatment for rheumatoid arthritis effective the second timeFebruary 24, 2006A second course of methotrexate, the most commonly used drug to treat rheumatoid arthritis, is effective in nearly half of studied patients for whom a previous treatment with the drug was ineffective. These are the results of a study published today in Arthritis Research & Therapy, which also shows that a second treatment with methotrexate is particularly effective in patients who were given low dose methotrexate in their first treatment. Theresa Kapral and colleagues from the Medical University of Vienna, Austria recruited patients with rheumatoid arthritis who had had at least two treatments with an anti-arthritis drug. Kapral et al. identified 79 patients who had had a second methotrexate treatment lasting at least a year. The patients had terminated the first treatment either because it was ineffective or because of adverse events. Forty-two (53.2%) patients had an effective second treatment. The second treatment was effective in 23 (45.1%) of the patients who had stopped treatment because of inefficacy. Sixteen (66.7%) of the patients who had initially stopped treatment because of adverse events had a successful second treatment. The second treatment was more than twice as likely to be successful if the methotrexate dose in the first treatment had been low (lower or equal to 10mg per week) than if it had been high (greater than 17.5mg per week). There was no difference in efficacy between first and second treatment for other anti-arthritis drugs.
Physicians treating rheumatoid arthritis are in need of therapeutic options especially for patients with a history of repeated drug failures. The results of this study indicate that renewed institution of methotrexate might be one option that could be considered for the treatment of these patients. BioMed Central | |||||||||||||||||||||
|
Related Methotrexate Treatment News Articles Abatacept and infliximab improve clinical response over time in methotrexate-refractory RA patients New data presented today at EULAR 2008, the Annual Congress of the European League Against Rheumatism in Paris, France, show that over half of rheumatoid arthritis patients resistant to methotrexate monotherapy improved when either abatacept or infliximab were added to their methotrexate treatment regimen, with positive results sustained up to one year later. St. Jude gene study reveals basis of anticancer drug resistance in childhood leukemia The first analysis of the genetic determinants of resistance to the anti-cancer drug methotrexate in childhood acute lymphoblastic leukemia (ALL) could offer a pathway to predicting such resistance and treatments to overcome it, according to a St. Jude Children's Research Hospital study. More Methotrexate Treatment News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||